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Abstract
Aim: Immunosuppression has evolved since the first successful orthotopic heart transplant 50 years ago. Currently, 
calcineurin inhibitors lie at the focal point of the immunosuppressive regimen. However, these drugs exhibit a variety 
of side effects, including hyperglycaemia. This in turn compounds the risk of cardiovascular disease. There is conflict 
around which calcineurin inhibitor, tacrolimus or ciclosporin, is more likely to induce diabetes.
Methods: A retrospective analysis of data from 52 patients who had received a heart transplantation at the Scottish 
heart transplant unit between January 2011 and August 2017. All patients received a combination immunosuppressive 
regimen consisting of mycophenolate mofetil, corticosteroids and either tacrolimus or ciclosporin.  Fasting glucose levels 
were compared every 3 months after transplantation for a year. HbA1c was collected and compared at one interval 
during follow-up postoperatively. Statistical analysis was achieved using Students t-test for continuous variables and 
Chi-squared test for categorical variables.
Results: The drug regimens remained unchanged in the two cohorts over the study period. The fasting glucose of 
tacrolimus treated patients was higher over the 12-month period compared to ciclosporin treated patients (7.3 ± 1 vs . 
5.9 ± 0.5, P  = 0.017). The results were significantly higher in the tacrolimus group at 9 months (P  = 0.013). In contrast 
to these findings, HbA1c of the tacrolimus group was lower than the ciclosporin group, although there was no significant 
difference (38 ± 11.4 vs . 43 ± 1.3, P  = 0.104).
Conclusion: This study suggests a relationship between tacrolimus and rising fasting glucose among heart transplant 
population. However, a longer follow-up and control of confounding variables is required to denote the long-term impact 
of immunosuppression related diabetes in heart transplant patients.
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INTRODUCTION
Over the past 50 years, heart transplantation has evolved to become an acceptable treatment for end-stage 
heart failure. Immunosuppression has been pivotal to the success of this procedure. Many drugs have been 
involved in post-transplant immunosuppressive regimens. However, current guidelines recommend the use 
of calcineurin inhibitors, tacrolimus and ciclosporin. Due to the potency of these drugs, patients are prone 
to a variety of side effects including diabetes. Preventing post-transplant diabetes mellitus (PTDM) is an 
important element of successful immunosuppression in cardiac transplantation, as uncontrolled diabetes 
is associated with cardiovascular morbidity and mortality. This can be detrimental to heart transplant 
recipients as they are already at risk of cardiac allograft vasculopathy (CAV).
The aim of this paper is to retrospectively analyse the possibility of developing diabetes mellitus in heart 
transplant patients who have been treated with either a ciclosporin or tacrolimus-based regimen. This will 
be done by focusing on fasting glucose and HbA1c levels in 52 patients up to a year after transplantation.
History of heart transplantation
In 1967, Barnard[1] performed the first successful human-to-human heart transplant in Cape Town, South 
Africa. The techniques used during this operation were created by Dr. Norman Shumway several years 
earlier and are still used in modern times[1]. Although a breakthrough in science at the time, the patient 
died of Pseudomonas pneumonia on the 18th day postoperatively[1]. This highlighted concerns surrounding 
immunosuppressive regimen, an issue which would remain prevalent for subsequent years.
A year on from Barnard[1]’s success, more than 100 cardiac transplants were performed at transplant centres 
around the world. But due to the high risk of complications, the procedure soon declined with only 9 taking 
place in 1971. During this time, one-year survival was 30%[2]. A key advancement in rejection monitoring 
was the introduction of endomyocardial biopsy[3] and the classification of histological rejection[4]. This 
allowed clinicians to combine clinical and histological findings to make the diagnosis of rejection more 
accurate. Worldwide interest in heart transplantation was revived in the 1980s after an immunological 
milestone, the introduction of ciclosporin A.
Between April 2016 and March 2017, 197 heart transplants were performed in the UK[5] with one-year 
survival over 80%[6]. This is a testament to the progress made since the 1970’s. Nevertheless, there are still 
serious challenges facing the field, limiting the success of heart transplantation. Such barriers include 
CAV, a type of chronic rejection that results in hardened arteries. This can compromise long term survival 
of the cardiac allograft and ultimately lead to cardiac arrest. Another major barrier is created by chronic 
immunosuppression, which can result in drug induced complications including diabetes mellitus[7].
Overview of rejection immunology
Complex mechanisms of immunity pose a significant barrier to successful transplantation. In cardiac 
transplantation, the response to alloantigens is mediated by host T-cells. Peptide antigens are presented 
to T-cell receptors in the context of major histocompatibility complex, by antigen-presenting cells[8]. This 
binding leads to an increase in cytoplasmic calcium ions, which in turn activates the protein phosphatase, 
calcineurin. When activated, calcineurin dephosphorylates nuclear factor of activated T-cells (NFAT)[9]. 
Following this, NFAT triggers the upregulation IL-2 expression, leading to T-cell stimulation.
The adaptive response is efficiently suppressed by conventional drugs. But, when unsuccessful, alloimmune 
response can lead to destruction of the allograft (rejection). Rejection is categorised into three major types: 
hyperacute, acute and chronic. Due to effective screening (HLA and ABO blood-group cross-matching) 
on transplant recipients, hyperacute rejection is rare[10]. Although acute and chronic rejection are more 
common, the mechanisms involved are incompletely understood. There is, however, a variety of immune-
system components involved, including the T-cell response mentioned above[11]. 
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Despite the combination drug regimen targeting different stages of the immune response, illustrated in 
Figure 1, patients are still at risk of rejection. From 2010, 24% of heart transplant recipients have experienced 
rejection[12]. This suggests there is room for more pharmacological discovery in this area.
Immunosuppression regimens in transplantation
Immunosuppression aims to dampen the immune response in order to sufficiently permit engraftment of 
the transplant, while simultaneously being suitably specific such that other protective immune responses 
remain intact. This requires a complementary combination of medication that optimise immunosuppression 
while decreasing toxicity. To create this balance in regimen, drugs are provided at different doses and time-
points so their effects are maximised.
Immunosuppressive treatment consists of induction and maintenance regimens. Induction therapy is 
intense and occurs before, during and after transplantation in aim to markedly reduce rejection in early 
postoperative period. Rabbit derived lympholytic agent, anti-thymocyte globulin (rATG) is a standard 
induction drug given postoperatively. Immediate postoperative rATG therapy allows CNIs to be introduced 
later. CNIs are nephrotoxic, so this action avoids exacerbation of renal dysfunction. Batches of rATG vary in 
potency, thus in order to assess the effectiveness, patients T cells should be monitored with flow cytometry[13].
Maintenance therapy consists of a combination of drugs including: an antiproliferative, a calcineurin 
inhibitor (CNI) and steroids. Although maintenance regimens are continually evolving, corticosteroids have 
remained at the core since the first heart transplantation. However, due to their significant side effects, the 
duration and dosage of corticosteroids has decreased with time[14]. To combat this issue, combination therapy 
has moved towards targeting steps in T-cell activation, permitting lower doses for each individual drug. 
Antiproliferative agents, Mycophenolate Mofetil (MMF) and Azathioprine, operate alongside other drugs 
to target the proliferation of T- and B-cells, resulting in diminished cytotoxic T-cell response[15,16]. MMF 
is recommended over due to its decreased incidence of rejection and CAV[17,18]. mTor inhibitors, such as 
Sirolimus, also target T-cell proliferation and are an effective alternative for CNI in patients with CNI 
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Figure 1. Four drug groups that make up the foundation of maintenance immunosuppression in heart transplantation
induced nephrotoxicity[19].
Ciclosporin
The discovery of ciclosporin in the early 1970s revolutionised the field of transplantation. Initially developed 
as an anti-fungal, the potent immunosuppressive properties of ciclosporin were first recognised in 1986 (Borel, 
1986). Ciclosporin was approved for use in kidney transplantation in 1979. This dramatically improved 
the mortality of transplant patients and provided sufficient evidence to permit approval for use in heart 
transplantation in 1980. Five years after introducing the drug to cardiac transplant recipients, Shumway’s 
group reported a 1-year survival rate of 83%[20]. In 1994, the original oil-based drug was replaced by a new 
micro-emulsion formulation (Neoral, Novartis). This provided greater bioavailability and more predictable 
pharmacokinetics, enhancing the role of ciclosporin in immunosuppression[21]. The use of ciclosporin in 
transplantation has led to a steady increase in survival, with worldwide 1-year survival now approaching 
90%[22].
The calcineurin inhibitor, ciclosporin inhibits T-cell proliferation by blocking its activation. When entering 
lymphocytes, ciclosporin binds to cyclophilin, a type of immunophilin. This ciclosporin-cyclophilin complex 
binds to and inhibits the action of calcineurin. As a result, the IL-2 transcription cascade is halted. This 
ultimately blocks T-cell activation, preventing allograft rejection process.
Tacrolimus
Tacrolimus, a macrolide antibiotic, was found to possess potent immunosuppressive qualities in 1984. The 
compound was first approved for use in transplantation in Japan, 1993[23]. Due to its decreased incidence 
of rejection when combined with MMF, tacrolimus has surpassed ciclosporin to become the cornerstone 
of immunosuppressant therapy today[24]. Over 70% of patients worldwide are on a tacrolimus and MMF 
combination therapy, further highlighting the superiority of tacrolimus[12]. 
Tacrolimus exhibits similar immunosuppressive activity to that of ciclosporin. However, tacrolimus inhibits 
calcineurin through binding to a different immunophilin, FK506 binding protein (FKBP12). Tacrolimus is 
also effective as a rescue rejection therapy[25].
Although CNIs play a critical role in the preservation of allograft function, these drugs cause a variety of 
side effects, including hyperglycaemia. This in turn can result in significant morbidity and reduced quality 
of life[26].
Post-transplant diabetes mellitus
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia, resulting from defects in insulin 
secretion, insulin action, or both[27]. There are several diagnostic tests for diabetes shown in Table 1, each 
test is used alongside any symptoms a patient is experiencing[28]. Although it has been proposed that PTDM 
could be a distinct entity, the natural history of diabetes after transplantation resembles type 2 diabetes[29]. 
Since the onset of both PTDM and type 2 diabetes can be insidious and patients may be asymptomatic for 
years before symptoms present. Accordingly, PTDM management follows the conventional approach used 
for patients with type 2 diabetes[30]. PTDM is not always permanent and may stabilise within weeks or 
months[31].
PTDM is a major problem among this population of patients as impaired glucose metabolism can contribute 
to increased risk of cardiovascular disease, subsequently reducing mortality in these patients.
CNI induced diabetes
The exact mechanism by which CNIs induce diabetes is unknown. One mechanism that has gained 
popularity involves calcineurin expression in pancreatic insulin-secreting b-cells. Here, calcineurin 
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undergoes a similar action to its role in T-cell activation. In pancreatic b-cells, the activation of calcineurin 
leads to the dephosphorisation and translocation of a different family of NFAT transcription factors. 
Following this, NFAT induces the expression of genes critical for multiple factors that control growth and 
hallmark b-cell functions, including insulin production and expression[19]. Therefore, calcineurin inhibition 
impairs b-cell proliferation and decreases b-cell mass resulting in reduced insulin expression. This ultimately 
leads to diabetes. 
In heart transplantation, diabetes is a well-recognised complication. More than 22% of heart transplant 
patients develop diabetes 1 year after transplantation[12]. Immunosuppressive agents contribute to this 
morbidity. Nevertheless, evidence surrounding which CNI is more likely to negatively affect glucose 
metabolism is contradictory. It is understood that both tacrolimus and ciclosporin are equivalent in inducing 
diabetes but it is suggested that, in clinical practice, tacrolimus has greater diabetogenic potential[32].
METHODS
Study population
A retrospective cohort study of 52 patients who underwent a first-time heart transplant at the Golden Jubilee 
National Hospital (Glasgow, Scotland) between January 2011 and August 2017. In January 2014, tacrolimus 
was made the primary CNI at the unit. As a result, 33 patients were on a tacrolimus-based maintenance 
regimen postoperatively. A comparable cohort of 19 patients on a ciclosporin-based maintenance regimen 
were selected. Prior to the investigation, one of the patients in the study population was diagnosed with 
diabetes. That patient was on a ciclosporin based regimen and included in the study. Patients who received 
changes in their drug regimens and patients who died were excluded. All patients were over the age of 18. 
Post-transplant Management
Each patient received immunosuppression according to the unit’s protocol. Immediate post-operative 
induction therapy consisted of rATG. This was given for up to 4 days after transplantation, until the 
patients kidney function is sufficient. Thereafter, patients received a combination regimen of CNI, MMF 
and a steroid. Patients remain on a CNI and MMF for their lifetime but steroids are removed 6 months 
after transplantation. Drug level monitoring was performed during routine follow-up visits at regular time 
intervals. Target CNI levels depend on time after transplantation, as illustrated in Table 2. These levels were 
collected and analysed in a laboratory at the Queen Elizabeth University Hospital, Glasgow, using tandem 
mass spectrometry.
Data collection and outcomes measured 
Data was collected from the transplant unit’s database. Clinical notes provided all the information necessary 
for analysis, including demographic information. Glucose metabolism was studied via fasting glucose levels 
Table 1. Diagnostic criteria for diabetes and pre-diabetes (WHO, 2006)
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Type of diagnostic test Normal Pre-diabetes Diabetes
Fasting glucose (mmol/L) < 5.5 5.5-7.0 > 7.0
Oral glucose tolerance test (mmol/L) < 7.8 7.8-11.1 > 11.1
HbA1c (mmol/L) < 42 42-47 > 47
Table 2. Target CNI levels of heart transplant patients in the Golden Jubilee National Hospital, Glasgow
Time after transplantation Tacrolimus (mg/L) target therapeutic range Time after transplantation
Ciclosporin (mg/L) target 
therapeutic range
0-3 months 10-15 0-4 weeks 240-300
3-6 months 8-12 1-6 months 160-200
6-12 months 7-10 6-12 months 130-160
> 12 months 5-7 > 12 months 64-96
and HbA1c. Fasting glucose levels were collected from five points in time; 1, 3, 6, 9 and 12 months post-
operatively. HbA1c was collected at one follow-up visit. The time points were chosen according to the post-
operative follow-up protocol used by the unit, this was consistent between patients. 
Statistical analysis 
Data was extracted, collated and stored on a Microsoft Excel 2017 spreadsheet. This data was then imported 
into Prism 7.0c software application for statistical analysis. Independent t-test was used to analyse any differ-
ences in continuous data and the Chi-squared test was used for categorical data. The level of significance was 
set at P-value < 0.05.
RESULTS
Patient demographics
Patient characteristics are listed in Table 3. The study groups were not matched, but all had appropriate 
clinical records and information that was accessible, allowing comparisons to be made. There was no 
statistical significant difference in the patient baseline characteristics, including age, gender and pre-
transplant diagnosis. Of the 52 patients enrolled, 5 had a diagnosis of diabetes, 4 of which were on a 
tacrolimus-based regimen and diagnosed after transplantation.
Laboratory Blood Glucose measurements
As mentioned previously, fasting glucose of the study population was collected at five different points of time 
postoperatively. This data was collated into a mean fasting glucose for each time-period, the results of which 
are presented in Table 4. At one month postoperatively, there was no statistical difference in fasting glucose 
between the two cohorts. Here, fasting glucose for the TAC cohort was 6.4 ± 1.7 mmol/L and 5.5 ± 1.3 mmol/L 
for the CyA cohort (P = 0.064). A fasting glucose of 6.4 mmol/L suggests TAC patients were pre-diabetic at 1 
month [Table 1]. 
In the first six months, there was a rise in fasting glucose among the TAC cohort, with levels peaking at the 
6-month follow-up. The fasting glucose of the TAC group at this stage was 8.8 mmol/L. This greatly exceeds 
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All (n  = 52) Tacrolimus & MMF (n  = 33) Ciclosporin & MMF (n  = 19) P -value
Age 50 ± 13 49 ± 12 51 ± 14 0.561
Male:female 37:15 24:9 13:6 0.741
Body Mass Index (kg/m2) 26.8 ± 4.6 25.4 ± 4.5 26.8 ± 4.8 0.103
Preoperative Diabetics 5 4 (12) 1 (5) 0.641
Creatinine 115.7 ± 40.3 119 ± 46.2 109.9 ± 27.3 0.440
Pre-transplant diagnosis
DCM
HCM
IHD
Other
32
4
9
7
18 (55)
3 (9)
6 (18)
6 (18)
14 (74)
1 (5)
3 (16)
1 (5) 0.479
Table 3. Selected demographic and baseline characteristics of the two patient groups
Table 4. Fasting glucose levels of the two cohorts over time
Fasting glucose (mmol/L) Tacrolimus & MMF (n  = 33) (mean ± SD) Ciclosporin & MMF (n  = 19) (Mean ± SD) P -value
BASELINE 5.9 ± 1.3 5.4 ± 0.9 0.726
  1 month 6.4 ± 1.7 5.5 ± 1.3 0.064
  3 months 7.8 ± 6.3 6.1 ± 1.6 0.275
  6 months 8.8 ± 7.5 5.9 ± 1.3 0.102
  9 months 6.9 ± 2.0 5.4 ± 1.4 0.013
  12 months 6.7 ± 3.7 6.5 ± 1.9 0.836
the diagnostic range for diabetes. The 6-month point also marks the largest difference between the two 
cohorts across the 12-month period, 8.8 ± 7.5 mmol/L vs. 5.9 ± 1.3 mmol/L (P = 0.102), this is highlighted in 
Figure 2.
During the first year after transplantation, drug dosage is monitored and adjusted cautiously according to the 
transplant unit’s target levels, incidence of transplant rejection and any side effects which may present, such 
as hyperglycaemia. Patients experiencing hyperglycaemia are followed up and managed according to the 
unit’s protocol. This includes reducing drug target levels for CNIs and providing appropriate management 
for the unbalanced glucose metabolism. 
Moreover, after 6-months fasting glucose declines across the population; this is especially seen in the TAC 
group. The difference in mean between the two cohorts shows significance at 9 months postoperatively, with 
the TAC cohort showing higher values. The mean fasting glucose was 6.9 ± 2.0 mmol/L in the TAC group 
and 5.4 ± 1.4 mmol/L in the CyA group (P = 0.013). 
One year after transplantation, mean fasting glucose of TAC cohort continued to decline. However, levels 
are still considered pre-diabetic and values are above the CyA group, 6.7 ± 3.7 mmol/L vs. 6.5 ± 1.9 mmol/L 
(P = 0.836). Nevertheless, the 12-month follow-up marks the highest mean fasting glucose levels for the CyA 
cohort. Consequently, CyA could possess a diabetogenic potential 12 months after transplantation. 
Overall, the mean fasting glucose over the 12-month period indicated significance. TAC treated patients had 
a higher mean fasting glucose, 7.3 ± 1.0 mmol/L, compared to the CyA cohort, 5.9 ± 0.5 mmol/L (P = 0.017). 
In contrast to the fasting glucose results, mean HbA1c of the TAC group was lower than the CyA group, as 
shown in Figure 3. These results however, did not reach statistical significance (P = 0.104). The mean HbA1c 
was collated from information at one interval for patients on both regimens. According to the diagnostic 
criteria [Table 1], CyA treated patients are pre-diabetic whilst TAC treated patients are not at risk of diabetes.
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Figure 2. Fasting blood glucose of heart transplant patients on tacrolimus or ciclosporin maintenance immunosuppression over time 
postoperatively (mean ± SD). At 9 months P  = 0.013
DISCUSSION
Principle findings
This study confirmed the risk of post-transplant diabetes is worse in heart transplant patients treated with 
tacrolimus-based maintenance immunosuppression compared with those treated with ciclosporin, when 
using mean fasting glucose as an indicator. The difference was significant at 9 months post-operatively. This 
timing fits with changes in the unit’s drug regimen, especially the removal of corticosteroids which also 
contribute to altered glucose metabolism. In both cohorts, fasting glucose normalises at 12 months, further 
emphasising the role of corticosteroids in the results produced. 
The mean HbA1c was greater in the ciclosporin treated cohort. At the beginning of the study, the two 
cohorts were comparable, with many relevant contributors to post-transplant diabetes considered- including 
age, sex, weight, creatinine, pretransplant diagnosis and diagnosis of diabetes. 
Context of research
Much evidence involving the effectiveness of both tacrolimus and ciclosporin is based on data from kidney 
and liver transplantation. For that reason, Reichart et al.[33] (2001) conducted a large European multicentre 
study to investigate the effectiveness of both CNIs in heart transplant recipients. With a study population 
of 82 patients across 5 centres, they found that when combined with azathioprine and corticosteroids, 
tacrolimus was just as effective as ciclosporin. While this three-year follow up confirmed tacrolimus a 
viable alternative for ciclosporin in heart transplantation, Reichart and colleagues also observed a higher 
proportion of patients treated with tacrolimus requiring insulin for PTDM, a consequence that would affect 
the morbidity and mortality of patients in years to come[33].
Another multicentre study published a few months later Taylor et al.[34] (1999) compared tacrolimus and 
ciclosporin to find both equally safe and effective maintenance immunosuppression in heart transplantation. 
They did observe a higher rate of hypertension and hyperlipidaemia in patients receiving tacrolimus. This 
was a significant finding as both hypertension and hyperlipidaemia negatively impact renal function. There 
was also no difference in the incidence of diabetes or hyperglycaemia between the two groups. This, at the 
time, differed from liver and kidney trials where diabetes was significantly more common in tacrolimus 
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Figure 3. HbA1c of heart transplant patients on tacrolimus or ciclosporin at one time interval (mean ± SD)
HbA1c of patients on tacrolimus or ciclosporin
38 ± 11.38
42 ± 1.26
treated patients. The results of this study confirmed the advantages of tacrolimus over ciclosporin.
Early studies used a combination of azathioprine and corticosteroids with either tacrolimus or ciclosporin. 
Nevertheless, since its use in the first heart transplant operation, treatment with azathioprine has been 
replaced in clinical practice by MMF due to its increased toxicity. An early investigation into the substitution 
of MMF for azathioprine found that in 650 heart transplant patients, MMF was more effective in reducing 
mortality and rejection and was associated with decreased toxicity[18]. In the 2000’s, Kobashigawa and 
colleagues further investigated this area. They found that a combination of tacrolimus and MMF offered 
more advantages than ciclosporin and MMF in cardiac transplant patients, including fewer rejections and 
an improved side effect profile. Post-transplant diabetic rates were greater among the tacrolimus and MMF 
treated group, although this difference was not statistically significant[35]. The PTDM results Kobashigawa 
produced reflect similarity with the current study. 
In the studies mentioned above, all patients are followed for a short time interval. Trials comparing triple 
immunosuppressive strategies involving tacrolimus or ciclosporin with MMF and steroids over a long term 
are rarely published. Guethoff et al.[36] (2013) used prospective randomised trial to follow-up heart transplant 
patients over 10 years. Long term analysis found a lower incidence of rejection in the tacrolimus group, but 
there was no difference between groups in long-term survival[36].
Clinical trials have been principle to the success of heart transplantation. Despite the vast number of trials, 
there is no single validated immunosuppression regimen. Nevertheless, protocols used worldwide in 2017 are 
strongly influenced by the results of SYMPHONY study which demonstrated that a low dose of tacrolimus, 
MMF and corticosteroids had the best allograft outcomes[37].
Since the superior rejection profile of tacrolimus has been established, research has been directed towards 
the side effects produced by the two CNIs and the consequences of this. However, there is limited data 
surrounding the onset of diabetes after tacrolimus or ciclosporin treatment in cardiac transplant patients. 
A large European multicentre trial published by Grimm et al.[38] (2006) revealed the incidence of PTDM 
in heart transplantation was significantly higher in the tacrolimus group. Accordingly, more tacrolimus 
patients required insulin therapy[38].
Grimm et al.[38]’s results highlighting the diabetogenic potential of tacrolimus, it should be noted that 
published studies in this area have often failed to reach significance to due low patient numbers. A study by 
Teebken et al.[39] (2002) reflects this, as out of 32 heart transplant recipients, 4 patients treated with tacrolimus 
developed PTDM compared with 1 patient treated with ciclosporin. The small sample size makes these 
results difficult to statistically analyse and compare.
 
Corticosteroids are also associated with a greater risk of developing diabetes after heart transplantation. 
Heart transplant recipients developing diabetes were found to be receiving higher mean doses of 
prednisolone compared to those without the condition[40]. Consequently, an increased number of studies 
are considering the effect of corticosteroid-sparing and corticosteroid-free regimens on the development 
of PTDM. Baran et al.[41] (2002) have shown that tapering of and weaning patients from corticosteroid 
treatment considerably lowered the incidence of diabetes.
Impact of PTDM on heart transplantation
PTDM has been a recognised complication of transplantation for several years, despite this, the importance 
of the condition has been underestimated. In the general population, it is putative that diabetes increases risk 
of cardiovascular disease (CVD). Nonetheless, the complications associated with diabetes were not thought 
to be a concern for patients who had undergone heart transplantation. Initial studies into the effect of PTDM 
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on transplant patients focused on kidney transplantation. Lindholm et al.[42] (1995) demonstrated that PTDM 
increased the risk of CVD in transplant recipients. The relationship between PTDM and CVD is a concern 
in heart transplant patients, as these patients are already at risk of CAV. As previously mentioned, CAV is an 
accelerated form of coronary artery disease, it is also a major cause of death in patients surviving over a year 
after heart transplantation[43].
A study by Kato et al.[44] (2004) looked at the relationship between glucose intolerance and CVD in 151 
heart transplant recipients. The researchers used HbA1c as an indicator of glucose metabolism and found 
that increased HbA1c levels were associated with occurrence of CVD and could play a pivotal role in 
its pathogenesis[44]. A limitation of this study and many others in this area is the lack of information 
surrounding the outcome of CVD in this population of patients. While it is important for clinicians 
to recognise the link between PTDM and CVD, the management and consequences of this need to be 
addressed.
Individuals with prediabetes are also at risk of CVD. Elevated fasting glucose among this group results 
from both impaired insulin action and secretion[45]. A meta-analysis comprising 1,611,399 individuals 
conducted by Huang et al.[46] (2016) found that prediabetes was associated with increased risk of composite 
cardiovascular events which all lead to mortality. They also observed increased risk occurring when fasting 
glucose was as low as 5.6 mmol/L.
In this study, it has been shown that patients on tacrolimus were prediabetic throughout the duration of the 
trial, with levels considerably higher than 5.6 mmol/L. It is therefore essential to not only focus on a blood 
test for diagnosis of diabetes but also any symptoms a patient may be experiencing. However, the study 
published by Huang et al.[46] consisted of data that was not specific to the transplant field. It is therefore 
difficult to generalise Huang’s results to the current study’s population of patients. There is scope for research 
in this area as data regarding the cardiovascular implications of prediabetes in heart transplant patients is 
lacking. 
Limitations of the study
Retrospective studies are prone to limitations which can affect the reliability of any results and conclusions 
produced. This study is prone to selection bias as data used was collected from patient files, as a result there 
was no participation selection. 
The data for this study was collected from patient files where information was transplant specific. Therefore, 
data that could influence the risk of diabetes was not measured, such as family history of diabetes and 
ethnicity. Ideally, HbA1c would be collected at different time points after transplantation. However, there 
was only one measurement available for both cohorts and so it is difficult to compare the results of the mean 
fasting glucose and HbA1c.
The use of a steroid in immunosuppressive maintenance therapy is a significant confounding factor in 
this study. As mentioned previously, a common side effect of steroid use is hyperglycaemia. Patients were 
followed up for a 12-month period, so fluctuating fasting glucose levels seen may be a result of steroid use. 
As steroids are removed from the regimen at 6 months, following up patients for a longer period could 
eliminate this cofounding variable.
As well as a short follow up, this was a single centre study consisting of 52 patients. These factors can create 
lack of external validity as results are difficult to generalise. Nonetheless, because the study was carried out 
in one unit, all patients received similar care, similar selection for surgery, drug regimens and follow-up. 
These factors give validity to the findings of this study.
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Due to the nature of this study, follow-up times were not exactly on time for each patient, but for this study, 
flexibility of two weeks was allowed in data collection. All information was readily available and there were 
no technical difficulties faced during this study.
Implications
Understanding the risk of hyperglycaemia with different maintenance immunosuppressant regimens 
is very important as chronic hyperglycaemia can negatively affect a patient’s quality of life and can 
result in high morbidity and mortality. A major modifiable risk factor for the development of PTDM is 
immunosuppression, but risk versus benefit analysis is needed to balance the risk of developing PTDM 
versus rejection. This study does not support the view of switching patients from tacrolimus to ciclosporin. 
Rejection episodes and survival data collection were not included in the study; therefore, this study cannot 
comment on the superiority of one drug over the other.
Instead, implications lie in informing clinicians about the possibility of developing diabetes after tacrolimus 
use and the complications of this on patients. Therefore, greater attention should be paid to recognising 
diabetes through different glycaemic parameters. As a result of the findings of this study, the heart transplant 
unit at the Golden Jubilee National Hospital has introduced regular HbA1c testing in all heart transplant 
patients. A HbA1c diagnosis of diabetes is already endorsed in the general population and should be used to 
recognise PTDM, especially due to its ability to predict diabetic complications.
Hyperglycaemia is extremely common in the early postoperative period. It can also occur because of critical 
conditions such as infections or as a consequence of rejection therapy. In this study, there is no data on 
patient glucose metabolism before transplantation. This would be helpful when making a formal diagnosis of 
PTDM, as the patient’s pre-transplant glucose function can be compared to after transplantation when they 
are stable on their maintenance immunosuppression, have stable cardiac allograft function and no acute 
infections.
Further studies should consider collaborating and combining data that links fasting glucose and HbA1c with 
end points, including microvascular complications, cardiovascular events, patient and graft survival. There 
is also a need to facilitate clinical trials into the prevention of PTDM, one way by which this can be done is 
to identify patients at risk. A limitation of this study, as mentioned previously, is the lack of data. Patient risk 
factors for PTDM are well established and encompass general information such as family history of diabetes. 
There is a room for possibly preventing PTDM and its complications when such factors are collected.
The future of pharmacological management in transplant recipients is beyond calcineurin inhibitors. Based 
on this research and personal recommendation, more advanced immunological methods could reduce side-
effects produced currently. This could also help reach the ultimate goal of organ transplantation, which 
is the development of safe and effective regimens that manipulate host immune system into accepting 
transplanting organs in absence of immunosuppressive management or ‘tolerance’. This would prevent 
the morbidity of chronic immunosuppression including CVD. Nevertheless, CNIs have dominated 
transplantation for decades through targeting T-cells, a key player in rejection. Research surrounding the 
function and clinical effects of both tacrolimus and ciclosporin will be valuable for the manipulation of 
immune cells in the future.
In conclusion, both tacrolimus and ciclosporin continue to remain at the backbone of pharmacological 
management in heart transplant patients. Even though tacrolimus is a newer agent with a greater ability to 
prevent allograft rejection, patients are at increased risk of diabetes. Pharmacological development in this 
area is required as the gap between the need for cardiac transplantations worldwide and the development of 
effective immunosuppressant regimens is growing.  A heart transplantation can transform a patient’s life, 
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but this significant procedure can be jeopardised by co-morbidities associated with its management. As a 
result, a new heart may fail for the same reasons the original heart failed. 
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